Tens of Millions of J&J Doses Sit on Shelves, Await FDA Nod (2)

April 29, 2021, 9:53 PM

Emergent BioSolutions Inc. has produced more than 115 million doses of drug substance used in the Johnson & Johnson Covid-19 vaccine, according to a person familiar with the matter, 60 million doses of which are in vials and ready to deploy at U.S. regulators’ discretion.

The Gaithersburg, Maryland-based contract manufacturer has been producing the J&J single-shot vaccine since the fourth quarter of 2020, said the person. The size of the stockpile, which isn’t yet cleared by the Food and Drug Administration for release, hasn’t been previously reported.

A Biden administration official, speaking on condition of anonymity, said the figures were ...

To read the full article log in.

Learn more about a Bloomberg Law subscription